ERBB2 and breast carcinoma: Thus, our data are consistent with a model whereby ErbB2-dependent ERK activation downregulates IRF6, IRF6 downregulation causes reduction in the cellular BLNK levels, whereas BLNK loss in turn inactivates p38MAPK and thus blocks breast cancer cell anoikis (Fig. 6H).